Steve Pakola leaves Thrombogenics for Amakem

Dr Steve Pakola has taken the role of CMO at Amakem, having previously served as CMO of Thrombogenics, where he played a pivotal role in the development of the company's lead product, ocriplasmin, which is under review in Europe as a treatment for symptomatic vitreomacular adhesion and has been filed for priority review in the US. Dr Pakola has been replaced at Thrombogenics by Dr Aniz Girach, who joined the company a year and a half ago as global head of clinical ophthalmology and was previously vice-president of international clinical development of ophthalmology at Alcon.

Amakem has also appointed Dr George Lasezkay to its board of directors. Dr Lasezkay was previously corporate vice-president of corporate...